Nurix Therapeutics (NRIX) Free Cash Flow (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Free Cash Flow data on file, last reported at -$73.0 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$73.0 million, down 17.14% year-over-year; the trailing twelve-month figure through Feb 2026 was -$274.1 million (down 37.55% YoY), and the FY2025 annual result was -$263.5 million, down 44.88% from the prior year.
• Free Cash Flow advanced to -$73.0 million in Q1 2026 per NRIX's latest filing, from -$79.7 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $31.9 million in Q4 2023 and troughed at -$79.7 million in Q4 2025.
• A 5-year average of -$44.8 million and a median of -$45.3 million in 2022 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow slumped 707.14% in 2022, then surged 184.76% in 2023.
• A 5-year view of Free Cash Flow shows it stood at -$37.6 million in 2022, then surged by 184.76% to $31.9 million in 2023, then slumped by 259.56% to -$50.9 million in 2024, then plunged by 56.74% to -$79.7 million in 2025, then grew by 8.47% to -$73.0 million in 2026.
• Business Quant data shows NRIX's Free Cash Flow at -$73.0 million in Q1 2026, -$79.7 million in Q4 2025, and -$58.4 million in Q3 2025.